Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy - Wikidata - wikimedia - TriplyDB

Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy

Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy

http://www.wikidata.org/entity/Q36193367

about

Clinicoradiological spectrum of reversible splenial lesion syndrome (RESLES) in adults: a retrospective study of a rare entity Levetiracetam in the Treatment of Epileptic Seizures After Liver Transplantation Novel molecular triggers underlie valproate-induced liver injury and its alleviation by the omega-3 fatty acid DHA: role of inflammation and apoptosis Association between the blood concentrations of ammonia and carnitine/amino acid of schizophrenic patients treated with valproic acid.Changing incidence of hyperammonemia in Japan from 2006 to 2013: expansion of new antiepileptic drugs reduces the risk of hyperammonemia.Reversible Encephalopathy due to Valproic Acid Induced Hyperammonemia in a Patient with Bipolar I Disorder: A Cautionary Report.Carnitine and/or Acetylcarnitine Deficiency as a Cause of Higher Levels of Ammonia Gait instability in valproate-treated patients: Call to measure ammonia levels.Valproic acid-induced hyperammonemic encephalopathy in a full-term neonate: a brief review and case report.In response: Commentary on clinical significance of CYP2C9-status-guided valproic acid therapy in children.Risk of Microangiopathy in Patients with Epilepsy under Long-term Antiepileptic Drug Therapy.Hypoxic respiratory failure due to hyperammonemic encephalopathy induced by concurrent use of valproic acid and topiramate, a case report and review of the literature.Valproic acid induced acute liver injury resulting in hepatic encephalopathy- a case report and literature review

P2860

Q36152279-90C737E2-CE0F-44C6-86FA-3CF329C533D5 Q36255864-8B57735D-6225-4E51-82A3-A794CDCAD424 Q37097358-F578C564-17D8-4676-BBB4-E40DD688B387 Q40963325-F56B5357-9904-4F6A-9455-17DA2C086E4F Q41338021-2C02CDF3-39E5-41EE-AF1B-3C360D6FA1B7 Q42327075-59E553A2-EA55-4AB3-9473-4560916F3B59 Q42646705-B4FC4CFA-8604-4A26-A95F-1CC52B192910 Q47784978-95FAD522-197E-48BB-99BF-8A4E312F06FF Q53521796-91413250-CA7E-4851-B120-3B389773F551 Q53716299-294FCEAE-185A-4295-A15C-64F508A337F6 Q55037428-0A19256E-E6AD-41CA-B1E6-967D3E40FDA0 Q55243214-24BD8CC6-BBF5-41B9-8134-4CE4AA5F47D5 Q57814899-065FA9B7-3054-43C4-9A9A-CE5395205D5F

P2860

Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy

http://www.wikidata.org/entity/Q36193367

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy

@ast

Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy

@en

type

label

Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy

@ast

Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy

@en

prefLabel

Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy

@ast

Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy

@en

P1433

Q36193367-EB796332-16D1-4E79-8963-60A5E91A5EBE

P1476

Q36193367-D9D07B51-54ED-4522-8666-BF91661DDF2E

P2093

Q36193367-0FF3C8BA-EA0E-4E14-AF46-4572E1897702

Q36193367-19C05883-B7D2-41BA-8DC5-21873A1FBF5F

Q36193367-49611F1E-1548-4328-83A0-FAC1DDAAE1F1

Q36193367-52052DD7-4AB6-46F6-A03B-D80BC694047B

Q36193367-5C01B028-1886-42AB-AD71-196801D97FB3

Q36193367-69E900C5-369A-454A-8CED-BA6203C7BD3C

Q36193367-A0D351A4-32D2-49A7-95EC-B882C7EA11D3

Q36193367-D088D908-1EB2-4796-B068-4419894546BB

Q36193367-D4A8F744-CFE8-41EE-BCDD-9A49D0D67F6C

P2860

Q36193367-02DA1023-5EA1-4A43-9DD3-8F32E9B275E8

Q36193367-0CF05FFB-2B47-45B8-ABD9-9BD459FDA749

Q36193367-34FAB6D8-E92D-4A4E-A643-218B0AC94BCB

Q36193367-3F75E1CF-3ED5-4EA5-B2BD-0136A0B4C194

Q36193367-401A13F7-A6A4-4FF0-88DE-3B8852F6EE8E

Q36193367-4A85C8EC-7F76-4DE6-98B2-5B8F76EAE987

Q36193367-4B475B0F-7112-429B-85C0-DE5C2C3D19F0

Q36193367-4CA9A831-94D6-40AE-A8CA-89032E5D259E

Q36193367-4D2C5E9A-0B91-42A6-933C-E07F4315DC87

Q36193367-54D580F1-0725-4DE0-BEB2-EBB612AE9038

P304

Q36193367-89C237B3-7402-456A-B425-64F9366FB90F

P31

Q36193367-15935A59-4884-412D-B9F1-872B9E0B71C3

P356

Q36193367-1FC5D2FC-ACC3-46B1-875F-2C6D0581D3EB

P407

Q36193367-9D248224-43B9-493E-BE82-C1D82634745C

P433

Q36193367-190E2BAC-2B74-435B-A470-5D59F6F826A7

P478

Q36193367-6AAABEBF-4E4A-4BD2-8D6B-80B53D71479A

P577

Q36193367-A6E50CB0-8245-44CF-8A0C-4CFCF763FB9D

P698

Q36193367-87EC3155-D1B7-4D24-B09A-DC749DCA5932

P932

Q36193367-21C201B6-FC8A-4023-887A-E9ED60E432FA

P356

MD.0000000000000066

P1433

P1476

Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy

@en

P2093

Cheng-Hsien Lu

http://www.w3.org/2001/XMLSchema#string

Chi-Ren Huang

http://www.w3.org/2001/XMLSchema#string

Chih-Hsiang Lin

http://www.w3.org/2001/XMLSchema#string

Chiung-Chih Chang

http://www.w3.org/2001/XMLSchema#string

Nai-Ching Chen

http://www.w3.org/2001/XMLSchema#string

Wen-Neng Chang

http://www.w3.org/2001/XMLSchema#string

Yan-Ting Lu

http://www.w3.org/2001/XMLSchema#string

Yao-Chung Chuang

http://www.w3.org/2001/XMLSchema#string

Yu-Lung Tseng

http://www.w3.org/2001/XMLSchema#string

P2860

Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy

Valproate-induced hyperammonemic encephalopathy in the presence of topiramate

Hyperammonemia associated with valproic acid use in elderly psychiatric patients.

Side effects of valproate.

Topiramate enhances the risk of valproate-associated side effects in three children.

The importance of drug interactions in epilepsy therapy.

Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies.

Hyperammonemia due to valproic acid in the psychiatric setting.

Hyperammonemia in review: pathophysiology, diagnosis, and treatment.

Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs.

P304

e66

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MD.0000000000000066

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

93

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25192484

http://www.w3.org/2001/XMLSchema#string

P932

4616274

http://www.w3.org/2001/XMLSchema#string